Arlene Chapman to Aged
This is a "connection" page, showing publications Arlene Chapman has written about Aged.
Connection Strength
0.401
-
Genetic Variants Associated With Uncontrolled Blood Pressure on Thiazide Diuretic/ß-Blocker Combination Therapy in the PEAR (Pharmacogenomic Evaluation of Antihypertensive Responses) and INVEST (International Verapamil-SR Trandolapril Study) Trials. J Am Heart Assoc. 2017 Nov 02; 6(11).
Score: 0.047
-
Night blood pressure responses to atenolol and hydrochlorothiazide in black and white patients with essential hypertension. Am J Hypertens. 2014 Apr; 27(4):546-54.
Score: 0.035
-
Effects of Bardoxolone Methyl in Alport Syndrome. Clin J Am Soc Nephrol. 2022 12; 17(12):1763-1774.
Score: 0.017
-
Utilization of Cystatin C in the Outpatient Setting. Am J Nephrol. 2022; 53(7):534-541.
Score: 0.016
-
Health Disparities in Autosomal Dominant Polycystic Kidney Disease (ADPKD) in the United States. Clin J Am Soc Nephrol. 2022 07; 17(7):976-985.
Score: 0.016
-
Examination of Metoprolol Pharmacokinetics and Pharmacodynamics Across CYP2D6 Genotype-Derived Activity Scores. CPT Pharmacometrics Syst Pharmacol. 2020 12; 9(12):678-685.
Score: 0.014
-
The value of genotypic and imaging information to predict functional and structural outcomes in ADPKD. JCI Insight. 2020 08 06; 5(15).
Score: 0.014
-
Core Outcome Domains for Trials in Autosomal Dominant Polycystic Kidney Disease: An International Delphi Survey. Am J Kidney Dis. 2020 09; 76(3):361-373.
Score: 0.014
-
Plasma Renin Activity Is a Predictive Biomarker of Blood Pressure Response in European but not in African Americans With Uncomplicated Hypertension. Am J Hypertens. 2019 06 11; 32(7):668-675.
Score: 0.013
-
Genetic Variants Influencing Plasma Renin Activity in Hypertensive Patients From the PEAR Study (Pharmacogenomic Evaluation of Antihypertensive Responses). Circ Genom Precis Med. 2018 04; 11(4):e001854.
Score: 0.012
-
Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease. N Engl J Med. 2017 11 16; 377(20):1930-1942.
Score: 0.012
-
Blood pressure response to metoprolol and chlorthalidone in European and African Americans with hypertension. J Clin Hypertens (Greenwich). 2017 Dec; 19(12):1301-1308.
Score: 0.012
-
Rationale and Design of a Clinical Trial Investigating Tolvaptan Safety and Efficacy in Autosomal Dominant Polycystic Kidney Disease. Am J Nephrol. 2017; 45(3):257-266.
Score: 0.011
-
Chronic Kidney Disease Classification in Systolic Blood Pressure Intervention Trial: Comparison Using Modification of Diet in Renal Disease and CKD-Epidemiology Collaboration Definitions. Am J Nephrol. 2016; 44(2):130-40.
Score: 0.011
-
A Genetic Response Score for Hydrochlorothiazide Use: Insights From Genomics and Metabolomics Integration. Hypertension. 2016 09; 68(3):621-9.
Score: 0.011
-
Mutations in GANAB, Encoding the Glucosidase IIa Subunit, Cause Autosomal-Dominant Polycystic Kidney and Liver Disease. Am J Hum Genet. 2016 06 02; 98(6):1193-1207.
Score: 0.011
-
Albuminuria and tolvaptan in autosomal-dominant polycystic kidney disease: results of the TEMPO 3:4 Trial. Nephrol Dial Transplant. 2016 11; 31(11):1887-1894.
Score: 0.010
-
PTPRD gene associated with blood pressure response to atenolol and resistant hypertension. J Hypertens. 2015 Nov; 33(11):2278-85.
Score: 0.010
-
TET2 and CSMD1 genes affect SBP response to hydrochlorothiazide in never-treated essential hypertensives. J Hypertens. 2015 Jun; 33(6):1301-9.
Score: 0.010
-
Association of branched and aromatic amino acids levels with metabolic syndrome and impaired fasting glucose in hypertensive patients. Metab Syndr Relat Disord. 2015 Jun; 13(5):195-202.
Score: 0.010
-
Large-scale gene-centric analysis identifies polymorphisms for resistant hypertension. J Am Heart Assoc. 2014 Nov 10; 3(6):e001398.
Score: 0.010
-
Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. J Am Soc Nephrol. 2015 Jan; 26(1):160-72.
Score: 0.009
-
Is diabetes mellitus-linked amino acid signature associated with ß-blocker-induced impaired fasting glucose? Circ Cardiovasc Genet. 2014 Apr; 7(2):199-205.
Score: 0.009
-
Baseline predictors of central aortic blood pressure: a PEAR substudy. J Am Soc Hypertens. 2014 Mar; 8(3):152-8.
Score: 0.009
-
Urate transporter gene SLC22A12 polymorphisms associated with obesity and metabolic syndrome in Caucasians with hypertension. Kidney Blood Press Res. 2012; 35(6):477-82.
Score: 0.008
-
Blood pressure responses and metabolic effects of hydrochlorothiazide and atenolol. Am J Hypertens. 2012 Mar; 25(3):359-65.
Score: 0.008
-
Polymorphisms in genes coding for GRK2 and GRK5 and response differences in antihypertensive-treated patients. Pharmacogenet Genomics. 2011 Jan; 21(1):42-9.
Score: 0.007
-
Lack of association between polymorphisms in STK39, a putative thiazide response gene, and blood pressure response to hydrochlorothiazide. Pharmacogenet Genomics. 2010 Aug; 20(8):516-9.
Score: 0.007
-
Decreased incidence of NSF in patients on dialysis after changing gadolinium contrast-enhanced MRI protocols. J Magn Reson Imaging. 2010 Feb; 31(2):440-6.
Score: 0.007
-
Comparison of office, ambulatory, and home blood pressure antihypertensive response to atenolol and hydrochlorthiazide. J Clin Hypertens (Greenwich). 2010 Jan; 12(1):14-21.
Score: 0.007
-
Impact of abdominal obesity on incidence of adverse metabolic effects associated with antihypertensive medications. Hypertension. 2010 Jan; 55(1):61-8.
Score: 0.007
-
Lack of correlation between thiazide-induced hyperglycemia and hypokalemia: subgroup analysis of results from the pharmacogenomic evaluation of antihypertensive responses (PEAR) study. Pharmacotherapy. 2009 Oct; 29(10):1157-65.
Score: 0.007